Beta Bio: 3 Key Takeaways for Long-Term Investors

Beta Bio reported Q3 2026 net sales of $35.5 million with strong pharmacy channel momentum. The company received FDA clearance for Mint, its tubeless patch pump launching in Q1 2027, expected to drive significant growth. Management raised full-year 2026 revenue guidance and highlighted that Mint's gross margins could exceed current patch pump products within three years. The company is resubmitting its 3D Intelligence dosing algorithm application after addressing FDA feedback.

11/09/2026, 12:00 PM • The Motley Fool

BBNX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be entitled to compensation. The lead plaintiff deadline is November 3, 2026.

11/02/2026, 9:04 PM • GlobeNewswire

Deadline Alert: Beta Bionics, Inc. Investors Have Until November 3, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

Beta Bionics, Inc. investors have until November 3, 2026 to request appointment as lead plaintiff in a securities fraud class action lawsuit. The complaint alleges the company failed to disclose material adverse facts regarding FDA Form 483 findings, including over 18,000 complaints and life-threatening hypoglycemic events that were not properly investigated or reported. The stock fell 37% on January 9, 2026 following disappointing preliminary fourth quarter 2025 financial results.

11/02/2026, 2:55 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. alleging that the company made materially false and misleading statements regarding its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose FDA observations about quality management system deficiencies, device malfunctions, and unreported serious customer injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

11/01/2026, 1:00 PM • GlobeNewswire

BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm

A class action lawsuit has been filed against Beta Bionics, Inc. for making materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased shares between July 30, 2025 and February 24, 2026 have until November 3, 2026 to apply as lead plaintiff.

10/31/2026, 9:10 AM • GlobeNewswire

Kaplan Fox Alerts Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to an Upcoming Deadline of November 3, 2026 in the Securities Class Action

A securities class action lawsuit has been filed against Beta Bionics, Inc. for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious, life-threatening hypoglycemia incidents caused by device malfunctions in its iLet insulin pump, which were not properly disclosed. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about the severity of patient incidents. The deadline to move the court to become lead plaintiff is November 3, 2026.

10/30/2026, 1:00 PM • GlobeNewswire

BBNX DEADLINE NOTICE: ROSEN, A LONGSTANDING FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The lawsuit claims thousands of complaints were filed with the FDA, contradicting defendants' assertions that the issues were benign. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

10/29/2026, 9:05 PM • GlobeNewswire

Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance – Hagens Berman

Beta Bionics (NASDAQ: BBNX) is facing a securities class action lawsuit for allegedly concealing FDA compliance issues and safety warnings regarding its iLet Bionic Pancreas insulin delivery system. The company failed to disclose over 18,000 unreported customer complaints about device functionality and severe hypoglycemia events detailed in an FDA Form 483 from June 2025. Stock prices fell 37% on January 8, 2026 after missing patient start expectations, and further declined following the FDA's public Warning Letter on February 24, 2026. The lead plaintiff deadline is November 3, 2026.

10/28/2026, 5:53 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose serious safety deficiencies, quality management issues, and unreported customer complaints involving serious injuries, thereby understating regulatory risks and safety concerns.

10/28/2026, 1:00 PM • GlobeNewswire

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels and causing hundreds of life-threatening hypoglycemic events. The company allegedly failed to disclose thousands of customer complaints to the FDA and misrepresented the scope of FDA Form 483 findings. Investors who purchased stock between July 30, 2025 and February 24, 2026 can join the lawsuit with a November 3, 2026 deadline to request lead plaintiff status.

10/27/2026, 9:37 PM • GlobeNewswire

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

A federal securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) for making false and misleading statements about its iLet Bionic Pancreas insulin pump. The company allegedly misrepresented FDA inspection findings and failed to report serious device malfunctions to investors. Shareholders who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to seek lead plaintiff status.

10/26/2026, 10:00 AM • GlobeNewswire

BBNX 9-DAY DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

Beta Bionics (NASDAQ: BBNX) is facing a securities class action lawsuit for allegedly concealing critical FDA compliance issues and device safety warnings. The complaint alleges the company failed to disclose over 18,000 unreported customer complaints regarding the iLet Bionic Pancreas, including algorithm failures and severe hypoglycemia events. Stock declined 37% on January 8, 2026 after missing patient start expectations, and further dropped following an FDA Warning Letter on February 24, 2026. The lead plaintiff deadline is November 3, 2026.

10/25/2026, 2:25 PM • GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Millrose Properties, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRP

Multiple securities class action lawsuits have been filed against several companies including Millrose Properties, Gildan Activewear, J.B. Hunt Transport Services, Beta Bionics, Hims & Hers Health, and Flotek Industries. Investors who purchased securities during specified class periods are encouraged to contact legal counsel before upcoming lead plaintiff deadlines. The lawsuits allege material misrepresentations and non-disclosures regarding business operations and financial performance.

10/25/2026, 2:05 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding the safety and regulatory compliance of its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose FDA observations about quality management system deficiencies and underreported serious customer complaints. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the lawsuit, with a lead plaintiff deadline of November 3, 2026.

10/25/2026, 1:00 PM • GlobeNewswire

PZZA DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Papa John’s International, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - PZZA

Rosen Law Firm issued deadline notices for multiple securities class action lawsuits. Papa John's investors have until November 2, 2026 to join litigation alleging the company made false statements about its transformation strategy and concealed market share losses. Similar deadline notices were issued for York Space Systems (October 30 deadline) and Beta Bionics (November 3 deadline).

10/24/2026, 6:12 PM • GlobeNewswire